JOHNSON & JOHNSON

Official Publications Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 21:00:02 26/04/2024 BST			5-day change	1st Jan Change
146.1 ^USD	-0.46%		-1.20%	-6.76%

04-26	Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment	MT
04-25	Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	MT

Official Publications

SEC Filing 8K	04-15	CO
Slide show Q1	04-15	CO
1st quarter results	04-15	CO
SEC Filing 13G	04-09	CO
Proxy Statments	03-12	CO
SEC Filing 10K	02-15	CO
SEC Filing 13G	01-23	CO
SEC Filing 8K	01-22	CO
Slide show results	01-22	CO
Annual results	01-22	CO
SEC Filing 8K	12-04	CO
SEC Filing 8K	11-29	CO
SEC Filing 8K	11-20	CO
SEC Filing 10Q-3	26/10/23	CO
SEC Filing 8K	19/10/23	CO
Slide show Q3	16/10/23	CO
3rd quarter results	16/10/23	CO
SEC Filing 8K	16/10/23	CO
SEC Filing 8K	29/08/23	CO
SEC Filing 8K	22/08/23	CO
SEC Filing 10Q-2	30/07/23	CO
SEC Filing 8K	27/07/23	CO
1st-half-year results	19/07/23	CO
SEC Filing 8K	19/07/23	CO
SEC Filing 8K	02/05/23	CO

1 2 3

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer